Access to healthcare remains a humanitarian crisis across Low- and Middle-Income Countries with millions of unnecessary preventable deaths. Three key challenges stand out
Access to quality medicines and healthcare remains poor across most of the world’s countries, with LMICs being 12 times more likely to face critical medicine shortages and unaffordability of medicines compared to high income countries
Healthcare systems across LMICs remain significant underfunded with just 6.8% of global healthcare spend attributable to LMICs. LMICs face a doctor-to-patients ratio of 0.2 per 1,000 vs. the WHO’s benchmark of 1.15 per 1,000 (6x lower than recommended)
Fully public and fully private efforts have not made a significant improvement, and insufficient financial incentives exist for big private corporate efforts. Further, 93.2% of healthcare spend goes to top 20 countries with only 6.8% going to low income countries
Deploying the healthcare utility commercial model focused on long-term impact with profits re-invested in key partners’ healthcare projects to meet both government and corporate goals
We negotiate best prices and bring outsized purchasing power by aggregating demand across LMICs. Quality & original branded treatments reach patients at guaranteed low costs patients at guaranteed low costs
We provide a long-term development opportunity to bring high-quality therapies to patients, while focusing on core business and operations.
We provide a long-term development opportunity to bring high-quality therapies to patients, while focusing on core business and operations.
Our Portfolio
Within the CRM therapeutic area, AxmedRx covers three main disease areas that address the largest burdens of disease across LMICs
Within the Oncology therapeutic area, AxmedRx covers five main disease areas that address the largest burdens of disease across LMICs:
Within our programmatic portfolio, we will initially focus on Sickle Cell Disease.
The reason why we exist and what drives all our operations & investments, ever since our foundation, is driven by a passion to have a positive impact in healthcare.
We are on a relentless pursuit of equity for all patients around the world. Every decision we make is rooted in making it easier for patients that need access to care to reach it
Dreams like the one fueling AXMEDRx can only be achieved through the excellent and relentless execution of the risk-taking and high-performant talent that we have on board.
Our mission brings together talented people, partners, governments and organizations that want to replenish today’s world with kindness and compassion. It is our “modus operandi”, internally, with our partners and with customers.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
Chief Strategy Officer
Harvard MBA | CEU, M.Pharm.
Chief Impact Officer
Harvard, MPA
Chief Commercial Officer
Geneva & Princeton, PhD
Founder & CEO
Harvard, MPA | Cambridge, M.Phil.
Co-Founder & Chief Strategy Officer
Harvard University, MBA (current)
CEU University, M.Pharm.
© 2023 | All Rights Reserved | Powered by Globiz Technology Inc.
